University of California

The United States Government As Represented by the Department of Veterans Affairs

Warsaw Orthopedic, Inc.

Other

Collabcom Ii, LLC

C. R. Bard, Inc.

Zimmer Spine, Inc.

Life Spine, Inc.

Aesculap Implant Systems, LLC

Flexuspine Inc.

Collabcoml, LLC

Jeffrey Chun Wang

Samuel S Murray

Keyvan Behnam

Elsa J Murray

Elsa J Brochmann-Murray

Alan W Cannon

Adrian Slattery

Thomas Neil Scioscia

Gregory C Marik

William Barry Null

John G Heller

Robert W Weakley

Michael S Butler

Michael E Landry

Erik J Wagner

Hyun W Bae

Gene P DiPoto

John Peter Unger

Michael Adam Randall

Michael Schular

Christopher I Shaffrey

Jim A Youssef

Majid Mehrpouyan

Marybeth Sharkey

Dean G Karahalios

Eric A Potts

Andrew McCormick Dickson

Oleg Guryev

Hiep Do

Brian Hewko

Chad E Ryshkus

Janzen Lo

James S Harrop

Alan S Hilibrand

Emily Goel

Cyal Lecy

Elena Afonina

Oleg Stanilevskiy

Ashwini D Sharan

Robert F Heary

Ian Schorn

Kirsten Ryan

Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.

Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents

Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.

Medical device with drug-eluting coating on modified device surface

Laminoplasty plates are engageable to at least one portion of a divided lamina to maintain a desired spacing relative to the spinal canal. The laminoplasty plates include a spacer portion having a first end and a second end that spans a gap formed by at least one of a divided lamina portion. The laminoplasty plates can include a lamina engagement portion at one end for engagement with the divided lamina portion.

Laminoplasty devices and methods

A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.

Bone morphogenic protein binding peptide

The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical co-morbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.

Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP)

The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.

Surgical applications for BMP binding protein

The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.

Devices, tools and methods for minimally invasive implantation and distraction between spinous processes for treatment of spinous disorders. An interspinous implant device for distracting at least one pair of adjacent spinous processes includes a main body including a shaft having a longitudinal axis; and first and second arms extending transversely from the main body, wherein at least one of the first and second arms is slidably mounted with respect to the shaft. The arms are configured and dimensioned to extend laterally from both sides of the spinous processes when implanted therebetween and to be inserted between the spinous processes laterally from a single side thereof. The arms are variably positionable between a closed configuration, to facilitate insertion of the arms between the adjacent spinous processes, and an open configuration, in which the arms are separated from one another.

Interspinous implant, tools and methods of implanting

Provided herein is tumor suppression composition and methods of making and using the same.

Compositions comprising spp24 peptide fragments

One exemplary device includes a main body including a shaft having a longitudinal axis; a first clamping mechanism having first and second jaws configured to clamp a spinous process of a first vertebra, and a second clamping mechanism having third and fourth jaws configured to clamp a spinous process of a second vertebra. The first, second, third and fourth jaws extend transversely from the shaft and at least two of two of the jaws are releasably mounted to the shaft and are mountable to and removable from the shaft by relative movement between the respective jaw and the shaft in a direction normal to a longitudinal axis of the shaft.

Devices, tools and methods for minimally invasive implantation of a dynamic interspinous implant device for distracting between spinous processes and providing dynamic stabilization. One exemplary device includes a main body including a shaft having a longitudinal axis; a first clamping mechanism having first and second jaws configured to clamp a spinous process of a first vertebra, and a second clamping mechanism having third and fourth jaws configured to clamp a spinous process of a second vertebra. The first, second, third and fourth jaws extend transversely from the shaft and at least two of two of the jaws are releasably mounted to the shaft and are mountable to and removable from the shaft by relative movement between the respective jaw and the shaft in a direction normal to a longitudinal axis of the shaft. The shaft has sufficient columnar strength to maintain distraction between the first and second vertebrae via the clamps, while also allowing at least one of the relative movements between the first and second vertebrae selected from the movements including lateral bending, flexion, extension and axial rotation.

Growing community of inventors

Sherman Oaks, CA, United States of America

Jeffrey Chun Wang